Cambridge startup Intellia Therapeutics Inc. announced Wednesday that it is pushing back a highly anticipated human trial of its lead gene editing treatment.
Intellia (Nasdaq: NTLA) announced Wednesday that it now plans to seek FDA approval in 2020 to start a clinical trial of the rare disease treatment, which uses gene editing technology known as CRISPR/Cas9. The company had originally planned to file the so-called IND application with the FDA by the end of 2019.
During a third quarter earnings…
Source: Boston Biz